A Multicentre Randomised Phase II Study of mFOLFOXIRI Versus mFOLFOX6 in Combination With Bevacizumab or Cetuximab as First-Line Treatment for Patients With Metastatic Colorectal Cancer
收藏NIAID Data Ecosystem2026-03-12 收录
官方服务：
资源简介：
Interventions: experimental group:mFOLFOXIRI combined with Bevacizumab/Cetuximab;control group:mFOLFOX6 combined with Bevacizumab/Cetuximab Primary outcome(s): objective response rate Study Design: Parallel
创建时间：
2020-09-15
